Cantor Fitzgerald restated their hold rating on shares of Novavax (NASDAQ:NVAX) in a research note published on Monday, December 18th. The firm currently has a $2.00 price objective on the biopharmaceutical company’s stock.
“The NanoFlu vaccine top-line data release we previewed as a potentially important catalyst before YE17 is now expected to occur in February 2018.”,” Cantor Fitzgerald’s analyst commented.
Other analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Novavax from a buy rating to a hold rating in a research report on Saturday, December 2nd. Zacks Investment Research downgraded shares of Novavax from a hold rating to a sell rating in a research report on Thursday, November 16th. Seaport Global Securities reaffirmed a neutral rating on shares of Novavax in a research report on Friday, October 6th. Finally, Citigroup raised shares of Novavax from a neutral rating to a buy rating and set a $2.00 price objective for the company in a research report on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. Novavax has an average rating of Hold and an average price target of $3.68.
Shares of Novavax (NASDAQ NVAX) traded down $0.37 during mid-day trading on Monday, hitting $1.61. 31,501,010 shares of the stock traded hands, compared to its average volume of 10,250,000. The stock has a market cap of $504.92, a price-to-earnings ratio of -2.37 and a beta of 2.03. Novavax has a 1-year low of $0.73 and a 1-year high of $2.14. The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31.
Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. The business had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.42 million. During the same quarter in the previous year, the business posted ($0.24) EPS. The company’s quarterly revenue was up 158.5% on a year-over-year basis. equities analysts expect that Novavax will post -0.62 earnings per share for the current year.
In related news, insider Stanley C. Erck bought 100,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were bought at an average cost of $1.13 per share, for a total transaction of $113,000.00. Following the completion of the purchase, the insider now owns 228,279 shares of the company’s stock, valued at approximately $257,955.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.00% of the company’s stock.
A number of hedge funds have recently bought and sold shares of NVAX. Geode Capital Management LLC raised its stake in shares of Novavax by 18.3% during the first quarter. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company’s stock valued at $3,073,000 after purchasing an additional 371,295 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in shares of Novavax by 287.7% during the second quarter. Canada Pension Plan Investment Board now owns 474,900 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 352,400 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Novavax by 39.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 1,153,971 shares of the biopharmaceutical company’s stock valued at $1,328,000 after purchasing an additional 326,415 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Novavax by 7.2% during the second quarter. Rhumbline Advisers now owns 346,968 shares of the biopharmaceutical company’s stock valued at $399,000 after purchasing an additional 23,410 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new stake in shares of Novavax during the second quarter valued at about $230,000. Institutional investors own 35.69% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Novavax (NVAX) Given Hold Rating at Cantor Fitzgerald” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/14/novavax-nvax-given-hold-rating-at-cantor-fitzgerald.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.